Cargando…

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts

BACKGROUND: External genital warts are caused by various subtypes of the human papilloma virus and spread through direct skin-to-skin contact. Approximately 1% of the US population have external genital warts. Although cantharidin has been used to treat external genital warts for decades, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Guenthner, Scott, McFalda, Wendy, Tate, Melita, Eads, Kimberly, Rieger, Jayson, Glover, David K., Willson, Cynthia, Rumney, Pamela, Rosen, Ted, Andres, Jennifer, Olivadoti, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436872/
https://www.ncbi.nlm.nih.gov/pubmed/34515985
http://dx.doi.org/10.1007/s40257-021-00635-2
_version_ 1783752063989055488
author Guenthner, Scott
McFalda, Wendy
Tate, Melita
Eads, Kimberly
Rieger, Jayson
Glover, David K.
Willson, Cynthia
Rumney, Pamela
Rosen, Ted
Andres, Jennifer
Olivadoti, Melissa
author_facet Guenthner, Scott
McFalda, Wendy
Tate, Melita
Eads, Kimberly
Rieger, Jayson
Glover, David K.
Willson, Cynthia
Rumney, Pamela
Rosen, Ted
Andres, Jennifer
Olivadoti, Melissa
author_sort Guenthner, Scott
collection PubMed
description BACKGROUND: External genital warts are caused by various subtypes of the human papilloma virus and spread through direct skin-to-skin contact. Approximately 1% of the US population have external genital warts. Although cantharidin has been used to treat external genital warts for decades, there are no US Food and Drug Administration-approved cantharidin products and no reliable or controlled sources of cantharidin available. VP-102 is a drug-device combination product containing cantharidin (0.7% w/v) in a single-use shelf-stable applicator. OBJECTIVE: The objective of this randomized, double-blind, vehicle-controlled, phase II clinical trial was to determine the optimal regimen for the treatment, safety, and efficacy of VP-102 in external genital warts. METHODS: The study was conducted in two parts. Part A was dose finding and Part B was performed following the completion of Part A for a safety and efficacy evaluation. Following completion of Part A, 6-h and 24-h VP-102 regimens under occlusion were selected to be evaluated in Part B. RESULTS: Pooled results from Part B and Part A of the 6-h and 24-h VP-102 treatment regimens showed that 36.7% and 33.3% of participants achieved complete clearance of all treatable external genital warts at the end of treatment vs 4.2% (p < 0.0048) and 0% (p < 0.0075) with the vehicle. Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity. The most common adverse events included application-site vesicles, pain, and erythema. No participants discontinued the study because of adverse events and no serious adverse events were deemed treatment related. CONCLUSIONS: The adverse event profile and efficacy of VP-102 under occlusion demonstrated in this study support the conclusion that a 6-h or up to 24-h exposure regimen represents an acceptable risk:benefit profile and justifies the conduct of a larger vehicle-controlled phase III study in external genital warts. CLINICAL TRIAL REGISTRATION: NCT03981822, actual study start date: 25 June, 2019; actual primary completion date: 21 May, 2020; actual study completion date: 8 July, 2020.
format Online
Article
Text
id pubmed-8436872
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84368722021-09-14 Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts Guenthner, Scott McFalda, Wendy Tate, Melita Eads, Kimberly Rieger, Jayson Glover, David K. Willson, Cynthia Rumney, Pamela Rosen, Ted Andres, Jennifer Olivadoti, Melissa Am J Clin Dermatol Original Research Article BACKGROUND: External genital warts are caused by various subtypes of the human papilloma virus and spread through direct skin-to-skin contact. Approximately 1% of the US population have external genital warts. Although cantharidin has been used to treat external genital warts for decades, there are no US Food and Drug Administration-approved cantharidin products and no reliable or controlled sources of cantharidin available. VP-102 is a drug-device combination product containing cantharidin (0.7% w/v) in a single-use shelf-stable applicator. OBJECTIVE: The objective of this randomized, double-blind, vehicle-controlled, phase II clinical trial was to determine the optimal regimen for the treatment, safety, and efficacy of VP-102 in external genital warts. METHODS: The study was conducted in two parts. Part A was dose finding and Part B was performed following the completion of Part A for a safety and efficacy evaluation. Following completion of Part A, 6-h and 24-h VP-102 regimens under occlusion were selected to be evaluated in Part B. RESULTS: Pooled results from Part B and Part A of the 6-h and 24-h VP-102 treatment regimens showed that 36.7% and 33.3% of participants achieved complete clearance of all treatable external genital warts at the end of treatment vs 4.2% (p < 0.0048) and 0% (p < 0.0075) with the vehicle. Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity. The most common adverse events included application-site vesicles, pain, and erythema. No participants discontinued the study because of adverse events and no serious adverse events were deemed treatment related. CONCLUSIONS: The adverse event profile and efficacy of VP-102 under occlusion demonstrated in this study support the conclusion that a 6-h or up to 24-h exposure regimen represents an acceptable risk:benefit profile and justifies the conduct of a larger vehicle-controlled phase III study in external genital warts. CLINICAL TRIAL REGISTRATION: NCT03981822, actual study start date: 25 June, 2019; actual primary completion date: 21 May, 2020; actual study completion date: 8 July, 2020. Springer International Publishing 2021-09-13 2021 /pmc/articles/PMC8436872/ /pubmed/34515985 http://dx.doi.org/10.1007/s40257-021-00635-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Guenthner, Scott
McFalda, Wendy
Tate, Melita
Eads, Kimberly
Rieger, Jayson
Glover, David K.
Willson, Cynthia
Rumney, Pamela
Rosen, Ted
Andres, Jennifer
Olivadoti, Melissa
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title_full Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title_fullStr Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title_full_unstemmed Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title_short Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
title_sort phase ii, double-blind, vehicle-controlled study to determine the cantharidin dose regimen, efficacy, safety, and tolerability of vp-102 in subjects with external genital warts
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436872/
https://www.ncbi.nlm.nih.gov/pubmed/34515985
http://dx.doi.org/10.1007/s40257-021-00635-2
work_keys_str_mv AT guenthnerscott phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT mcfaldawendy phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT tatemelita phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT eadskimberly phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT riegerjayson phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT gloverdavidk phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT willsoncynthia phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT rumneypamela phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT rosented phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT andresjennifer phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts
AT olivadotimelissa phaseiidoubleblindvehiclecontrolledstudytodeterminethecantharidindoseregimenefficacysafetyandtolerabilityofvp102insubjectswithexternalgenitalwarts